AstraZeneca PLC (AZN) Return on Invested Capital (ROIC): 13.03%
Is AstraZeneca PLC’s return on invested capital (ROIC) high or low?
AstraZeneca PLC's return on invested capital (ROIC) of 13.03% is 72% above its 5-year average of 7.60%, near the high end of its 5-year range (-0.54%–13.03%).
As of Sunday, June 14, 2026. 11.70% above its 12-month average of 11.66%.
AZN Return on Invested Capital (ROIC) Chart
AZN Average Return on Invested Capital (ROIC) Chart
AZN Current vs Average Return on Invested Capital (ROIC) Chart
AZN Return on Invested Capital (ROIC) Metrics
RETURN ON INVESTED CAPITAL (ROIC)
13.03%
RETURN ON INVESTED CAPITAL (ROIC) AVG TTM
11.66%
RETURN ON INVESTED CAPITAL (ROIC) AVG 3Y
9.40%
RETURN ON INVESTED CAPITAL (ROIC) AVG 5Y
7.60%
RETURN ON INVESTED CAPITAL (ROIC) AVG 10Y
7.56%
RETURN ON INVESTED CAPITAL (ROIC) AVG 15Y
9.97%
RETURN ON INVESTED CAPITAL (ROIC) AVG 20Y
12.76%
CURRENT VS TTM AVG
+11.70%
CURRENT VS 3Y AVG
+38.54%
CURRENT VS 5Y AVG
+71.56%
CURRENT VS 10Y AVG
+72.31%
CURRENT VS 15Y AVG
+30.72%
CURRENT VS 20Y AVG
+2.14%
AZN Competitors' Return on Invested Capital (ROIC)
| NAME | MARKET CAP | RETURN ON INVESTED CAPITAL (ROIC) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| AstraZeneca PLC (AZN) | $277.22B | 13.03% | 11.66% | 9.40% | 7.60% |
| Merck & Co., Inc. (MRK)vs › | $294.03B | 18.27% | 18.62% | 14.12% | 12.73% |
| Amgen Inc. (AMGN)vs › | $191.70B | 13.16% | 11.04% | 11.80% | 12.80% |
| UnitedHealth Group Incorporated (UNH)vs › | $371.00B | 8.23% | 10.28% | 12.20% | 12.63% |
| Thermo Fisher Scientific Inc. (TMO)vs › | $174.42B | 7.58% | 7.80% | 8.16% | 9.10% |
| Gilead Sciences, Inc. (GILD)vs › | $155.93B | 21.53% | 11.95% | 11.58% | 9.92% |
| Abbott Laboratories (ABT)vs › | $153.59B | 8.43% | 9.16% | 9.70% | 9.86% |
| AbbVie Inc. (ABBV)vs › | $402.35B | 12.97% | 10.91% | 11.35% | 11.16% |
| Pfizer Inc. (PFE)vs › | $149.38B | 8.84% | 9.06% | 10.60% | 10.43% |
| Intuitive Surgical, Inc. (ISRG)vs › | $145.58B | 13.71% | 12.85% | 12.25% | 11.92% |
Capital Efficiency
ROIC
13.0%
ROE
21.9%
AstraZeneca PLC Return on Invested Capital (ROIC) Formula & Definition
ROIC = NOPAT / Invested Capital
Return on invested capital measures the after-tax return a company earns on all capital (debt and equity) invested in the business.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
AstraZeneca PLC Return on Invested Capital (ROIC) FAQ
- What is the return on invested capital (ROIC) for AstraZeneca PLC (AZN)?
- The return on invested capital (ROIC) for AZN stock is 13.03%.
- Is AstraZeneca PLC's return on invested capital (ROIC) high or low?
- AstraZeneca PLC's return on invested capital (ROIC) of 13.03% is 72% above its 5-year average of 7.60%, near the high end of its 5-year range (-0.54%–13.03%).
- What is the TTM average return on invested capital (ROIC) for AstraZeneca PLC (AZN)?
- The TTM average return on invested capital (ROIC) for AZN stock is 11.66%.
- What is the 3Y average return on invested capital (ROIC) for AstraZeneca PLC (AZN)?
- The 3Y average return on invested capital (ROIC) for AZN stock is 9.40%.
- What is the 5Y average return on invested capital (ROIC) for AstraZeneca PLC (AZN)?
- The 5Y average return on invested capital (ROIC) for AZN stock is 7.60%.
- What is the 10Y average return on invested capital (ROIC) for AstraZeneca PLC (AZN)?
- The 10Y average return on invested capital (ROIC) for AZN stock is 7.56%.
- What is the 15Y average return on invested capital (ROIC) for AstraZeneca PLC (AZN)?
- The 15Y average return on invested capital (ROIC) for AZN stock is 9.97%.
- What is the 20Y average return on invested capital (ROIC) for AstraZeneca PLC (AZN)?
- The 20Y average return on invested capital (ROIC) for AZN stock is 12.76%.
AstraZeneca PLC Return on Invested Capital (ROIC) History
| DATE | RETURN ON INVESTED CAPITAL (ROIC) |
|---|---|
| 2025-12-31 | 13.03% |
| 2024-12-31 | 10.30% |
| 2023-12-31 | 9.32% |
| 2022-12-31 | 4.97% |
| 2021-12-31 | -0.54% |
| 2020-12-31 | 8.49% |
| 2019-12-31 | 5.12% |
| 2018-12-31 | 7.34% |
| 2017-12-31 | 7.47% |
| 2016-12-31 | 9.48% |
| 2015-12-31 | 8.20% |
| 2014-12-31 | 4.84% |
| 2013-12-31 | 7.02% |
| 2012-12-31 | 16.48% |
| 2011-12-31 | 26.53% |
| 2010-12-31 | 21.44% |
| 2009-12-31 | 20.55% |
| 2008-12-31 | 18.70% |
| 2007-12-31 | 15.40% |
| 2006-12-31 | 28.28% |
| 2005-12-31 | 25.47% |
| 2004-12-31 | 18.00% |
| 2003-12-31 | 18.66% |
| 2002-12-31 | 21.08% |
| 2001-12-31 | 17.18% |
| 2000-12-31 | 20.65% |
| 1999-12-31 | 18.37% |
| 1998-12-31 | 28.60% |
| 1997-12-31 | 22.12% |
| 1996-12-31 | 20.84% |
Related Metrics
About AstraZeneca PLC
AstraZeneca PLC operates as a global biopharmaceutical leader, dedicated to the entire process of bringing prescription medicines to market, from their initial discovery and development through manufacturing and commercialization. The company's extensive portfolio of treatments, including prominent examples like Tagrisso, Farxiga, and Symbicort, addresses critical areas such as cardiovascular, renal, metabolic, and oncological conditions. Furthermore, it provides essential solutions for COVID-19 and various rare diseases, with products like Vaxzevria and Soliris. AstraZeneca engages with primary and specialty care physicians worldwide, facilitating distribution through a robust network of representatives and local offices across the United Kingdom, continental Europe, the Americas, Asia, Africa, and Australasia. The firm actively drives innovation through strategic collaborations, partnering with entities such as Neurimmune AG for the development and commercialization of NI006, BenevolentAI for systemic lupus erythematosus drug discovery, Lunit for AI-powered digital pathology risk assessment in NSCLC, and Absci Corporation for AI-driven oncology target identification. Founded in 1992, the company was initially known as Zeneca Group PLC, subsequently rebranding to AstraZeneca PLC in April 1999, and maintains its headquarters in Cambridge, United Kingdom.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- CEO
- Pascal Claude Roland Soriot